Relevance of plasma obestatin and early arteriosclerosis in patients with type 2 diabetes mellitus

Journal of Diabetes Research

Volumn 2013, Issue , 2013, Pages

  Gu, Peng Ying ^a   Kang, Dong Mei ^a   Wang, Wei Dong ^a   Chen, Yan ^a   Zhao, Zhi Hong ^a   Zheng, Hui ^a   Ye, Shan Dong ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OBESTATIN; TRIACYLGLYCEROL; GHRELIN; OBESTATIN, HUMAN;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTERIOSCLEROSIS; ARTICLE; CARDIOVASCULAR RISK; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CAROTID ARTERY DISEASE; CASE CONTROL STUDY; DIABETIC ANGIOPATHY; DISEASE COURSE; ECHOGRAPHY; GLUCOSE INTOLERANCE; MIDDLE AGED; PATHOPHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; FEMALE; GHRELIN; GLUCOSE INTOLERANCE; HUMANS; MALE; MIDDLE AGED;

EID: 84890017640     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2013/563919     Document Type: Article

References (35)

1. Beckman J. A., Creager M. A., Libby P., Diabetes and atherosclerosis epidemiology, pathophysiology, and management. Journal of the American Medical Association 2002 287 19 2570 2581 2-s2.0-0037092995 (Pubitemid 34517204)
2. Kirpichnikov D., Sowers J. R., Diabetes mellitus and diabetes-associated vascular disease. Trends in Endocrinology and Metabolism 2001 12 5 225 230 2-s2.0-0035406633 (Pubitemid 33714209)
3. Pyorala K., Laakso M., Uusitupa M., Diabetes and atherosclerosis: an epidemiologic view. Diabetes/Metabolism Reviews 1987 3 2 463 524 2-s2.0-0023090431 (Pubitemid 17050766)
4. Haffner S. M., Lehto S., Rönnemaa T., Pyörälä K., Laakso M., Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. The New England Journal of Medicine 1998 339 4 229 234 2-s2.0-0032560807 10.1056/NEJM199807233390404 (Pubitemid 28350165)
5. Toussirot É., Streit G., Nguyen N. U., Dumoulin G., Le Huédé G., Saas P., Wendling D., Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. Metabolism 2007 56 10 1383 1389 2-s2.0-34548633198 10.1016/j.metabol.2007.05.009 (Pubitemid 47404601)
6. Vendrell J., Broch M., Vilarrasa N., Molina A., Gómez J. M., Gutiérrez C., Simón I., Soler J., Richart C., Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obesity Research 2004 12 6 962 971 2-s2.0-4644226667
7. Nathan D. M., Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the american diabetes association and the european association for the study of diabetes. Diabetes Care 2009 32 3 e37 e38 2-s2.0-64749100501 10.2337/dc08-2195
8. Fonseca V., Rosenstock J., Patwardhan R., Salzman A., Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. Journal of the American Medical Association 2000 283 13 1695 1702 2-s2.0-0034607438 (Pubitemid 30196209)
9. Nathan D. M., Initial management of glycemia in type 2 diabetes mellitus. The New England Journal of Medicine 2002 347 17 1342 1349 2-s2.0-0037167920 10.1056/NEJMcp021106 (Pubitemid 35215326)
10. Inzucchi S. E., Oral antihyperglycemic therapy for type 2 diabetes: scientific review. Journal of the American Medical Association 2002 287 3 360 372 2-s2.0-0037116638 (Pubitemid 34256388)
11. Klonoff D. C., Buse J. B., Nielsen L. L., Guan X., Bowlus C. L., Holcombe J. H., Wintle M. E., Maggs D. G., Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research and Opinion 2008 24 1 275 286 2-s2.0-38549162147 10.1185/030079907X253870 (Pubitemid 351160260)
12. Cui A.-D., Gai N.-N., Zhang X.-H., Decreased serum obestatin consequent upon TRIB3 Q84R polymorphism exacerbates carotid atherosclerosis in subjects with metabolic syndrome. Diabetology and Metabolic Syndrome 2012 4 1 1 5
13. Alloatti G., Arnoletti E., Bassino E., Penna C., Perrelli M. G., Ghé C., Muccioli G., Obestatin affords cardioprotection to the ischemic-reperfused isolated rat heart and inhibits apoptosis in cultures of similarly stressed cardiomyocytes. American Journal of Physiology 2010 299 2 H470 H481 2-s2.0-77955455608 10.1152/ajpheart.00800.2009
14. Zhang J. V., Ren P.-G., Avsian-Kretchmer O., Luo C.-W., Rauch R., Klein C., Hsueh A. J. W., Medicine: obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005 310 5750 996 999 2-s2.0-27744600963 10.1126/science.1117255 (Pubitemid 41611907)
15. Qader S. S., Håkanson R., Rehfeld J. F., Lundquist I., Salehi A., Proghrelin-derived peptides influence the secretion of insulin, glucagon, pancreatic polypeptide and somatostatin: a study on isolated islets from mouse and rat pancreas. Regulatory Peptides 2008 146 1-3 230 237 2-s2.0-38149098503 10.1016/j.regpep.2007.09.017
16. Kapica M., Zabielska M., Puzio I., Jankowska A., Kato I., Kuwahara A., Zabielski R., Obestatin stimulates the secretion of pancreatic juice enzymes through a vagal pathway in anaesthetized rats-preliminary results. Journal of Physiology and Pharmacology 2007 58 3 123 130 2-s2.0-34948884102 (Pubitemid 47523109)
17. Zhang J. V., Ren P.-G., Avsian-Kretchmer O., Luo C.-W., Rauch R., Klein C., Hsueh A. J. W., Medicine: Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005 310 5750 996 999 2-s2.0-27744600963 10.1126/science.1117255 (Pubitemid 41611907)
18. Catalán V., Gómez-Ambrosi J., Rotellar F., Silva C., Gil M. J., Rodríguez A., Cienfuegos J. A., Salvador J., Frühbeck G., The obestatin receptor (GPR39) is expressed in human adipose tissue and is down-regulated in obesity-associated type 2 diabetes mellitus. Clinical Endocrinology 2007 66 4 598 601 2-s2.0-33947220471 10.1111/j.1365-2265.2007. 02777.x (Pubitemid 46434943)
19. Mohr-Kahaly S., New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study. Journal of the American College of Cardiology 2001 37 6 1543 1550 2-s2.0-0035031972 10.1016/S0735-1097(01)01183-4 (Pubitemid 32385987)
20. Nakahara T., Harada T., Yasuhara D., Shimada N., Amitani H., Sakoguchi T., Kamiji M. M., Asakawa A., Inui A., Plasma obestatin concentrations are negatively correlated with body mass index, insulin resistance index, and plasma leptin concentrations in obesity and anorexia nervosa. Biological Psychiatry 2008 64 3 252 255 2-s2.0-46449120007 10.1016/j.biopsych.2007.08.005 (Pubitemid 351927261)
21. Gurriarán-Rodríguez U., Al-Massadi O., Roca-Rivada A., Obestatin as a regulator of adipocyte metabolism and adipogenesis. Journal of Cellular and Molecular Medicine 2011 15 9 1927 1940
22. Granata R., Gallo D., Luque R. M., Obestatin regulates adipocyte function and protects against diet-induced insulin resistance and inflammation. The FASEB Journal 2012 26 8 3393 3411 10.1096/fj.11-201343
23. Qi X., Li L., Yang G., Liu J., Li K., Tang Y., Liou H., Boden G., Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus. Clinical Endocrinology 2007 66 4 593 597 2-s2.0-33947199857 10.1111/j.1365-2265.2007.02776.x (Pubitemid 46434942)
24. Catalán V., Gómez-Ambrosi J., Rotellar F., Silva C., Gil M. J., Rodríguez A., Cienfuegos J. A., Salvador J., Frühbeck G., The obestatin receptor (GPR39) is expressed in human adipose tissue and is down-regulated in obesity-associated type 2 diabetes mellitus. Clinical Endocrinology 2007 66 4 598 601 2-s2.0-33947220471 10.1111/j.1365-2265.2007. 02777.x (Pubitemid 46434943)
25. St-Pierre D. H., Settanni F., Olivetti I., Gramaglia E., Tomelini M., Granata R., Prodam F., Benso A., Ghigo E., Broglio F., Circulating obestatin levels in normal and Type 2 diabetic subjects. Journal of Endocrinological Investigation 2010 33 4 211 214 2-s2.0-77953597024
26. Hodis H. N., Mack W. J., LaBree L., Selzer R. H., Liu C.-R., Liu C.-H., Azen S. P., The role of carotid arterial intima-media thickness in predicting clinical coronary events. Annals of Internal Medicine 1998 128 4 262 269 2-s2.0-0032519844 (Pubitemid 28090756)
27. Lorenz M. W., Markus H. S., Bots M. L., Rosvall M., Sitzer M., Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007 115 4 459 467 2-s2.0-33846609195 10.1161/CIRCULATIONAHA.106.628875 (Pubitemid 46184197)
28. Temelkova-Kurktschiev T., Koehler C., Henkel E., Hanefeld M., Leukocyte count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetes. Cardiovascular Research 2002 56 2 277 283 2-s2.0-0036838542 10.1016/S0008-6363(02)00547-3 (Pubitemid 35223498)
29. Brohall G., Odén A., Fagerberg B., Carotid artery intima-media thickness in patients with Type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabetic Medicine 2006 23 6 609 616 2-s2.0-33744813572 10.1111/j.1464-5491.2005.01725.x (Pubitemid 43830060)
30. Kim S. H., Lee S. J., Kang E. S., Kang S., Hur K. Y., Lee H. J., Ahn C. W., Cha B. S., Yoo J. S., Lee H. C., Effects of lifestyle modification on metabolic parameters and carotid intima-media thickness in patients with type 2 diabetes mellitus. Metabolism 2006 55 8 1053 1059 2-s2.0-33745917735 10.1016/j.metabol.2006.03.017 (Pubitemid 44040983)
31. Lee E. J., Kim H. J., Bae J. M., Kim J. C., Han H. J., Park C. S., Park N. H., Kim M. S., Ryu J. A., Relevance of common carotid intima-media thickness and carotid plaque as risk factors for ischemic stroke in patients with type 2 diabetes mellitus. American Journal of Neuroradiology 2007 28 5 916 919 2-s2.0-34248682163 (Pubitemid 46776074)
32. Kellokoski E., Kunnari A., Jokela M., Mäkelä S., Kesäniemi Y. A., Hörkkö S., Ghrelin and obestatin modulate early atherogenic processes on cells: enhancement of monocyte adhesion and oxidized low-density lipoprotein binding. Metabolism 2009 58 11 1572 1580 2-s2.0-70449728066 10.1016/j.metabol.2009.05.009
33. Alloatti G., Arnoletti E., Bassino E., Penna C., Perrelli M. G., Ghé C., Muccioli G., Obestatin affords cardioprotection to the ischemic-reperfused isolated rat heart and inhibits apoptosis in cultures of similarly stressed cardiomyocytes. American Journal of Physiology 2010 299 2 H470 H481 2-s2.0-77955455608 10.1152/ajpheart.00800.2009
34. Agnew A. J., Robinson E., McVicar C. M., Harvey A. P., Ali I. H. A., Lindsay J. E., McDonald D. M., Green B. D., Grieve D. J., The gastrointestinal peptide obestatin induces vascular relaxation via specific activation of endothelium-dependent NO signalling. British Journal of Pharmacology 2012 166 1 327 338 2-s2.0-84859722696 10.1111/j.1476-5381.2011.01761.x
35. Kellokoski E., Kunnari A., Jokela M., Mäkelä S., Kesäniemi Y. A., Hörkkö S., Ghrelin and obestatin modulate early atherogenic processes on cells: enhancement of monocyte adhesion and oxidized low-density lipoprotein binding. Metabolism 2009 58 11 1572 1580 2-s2.0-70449728066 10.1016/j.metabol.2009.05.009